30095-51-3

Upstream product

• 2845-89-8 1-chloro-3-methoxy-benzene 
• 41068-36-4 2-chloro-4-methoxyacetophenone 

Downstream Products

• 868861-16-9 4-(2-chloro-4-methoxyphenyl)-1,2-bis(4-methoxyphenyl)-1H-imidazole 
• 868861-17-0 2,4-bis(2-chloro-4-methoxyphenyl)-1-(4-methoxyphenyl)-1H-imidazole 
• 1001441-54-8 4-(2-chloro-4-methoxyphenyl)-1,2-bis(4-methoxyphenyl)-butane-1,4-dione 
• 1403674-80-5 5-(2-chloro-4-methoxyphenyl)-2,3-bis(4-methoxyphenyl)-1-methyl-1H-pyrrole 
• 220131-32-8 2'-chloro-4'-hydroxyphenacyl bromide 

Relevant academic research and scientific papers

Influence of chlorine or fluorine substitution on the estrogenic properties of 1-alkyl-2,3,5-tris(4-hydroxyphenyl)-1H-pyrroles

In continuation of our previous work, several 1-alkyl-2,3,5-tris(4- hydroxyphenyl)aryl-1H-pyrroles with chlorine or fluorine substituents in the aryl residues were synthesized and tested for estrogen receptor (ER) binding at isolated ERα/ERβ receptors (HAP assay) and in transactivation assays using ERα-positive MCF-7/2a as well as U2-OS/ERα and U2-OS/ERβ cells. In the competition experiment at ERα the compounds displayed very high relative binding affinities of up to 37% (determined for 8m) but with restricted subtype selectivity (e.g., ERα/ERβ (8m) = 9). The highest estrogenic potency in ERα-positive MCF-7/2a cells was determined for 2,3,5-tris(2-fluoro-4-hydroxyphenyl)-1-propyl-1H-pyrrole 8m (EC50 = 23 nM), while in U2-OS/ERα cells 2-(2-fluoro-4-hydroxyphenyl)-3,5-bis(4- hydroxyphenyl)-1-propyl-1H-pyrrole 8b (EC50 = 0.12 nM) was the most potent agonist, only 30-fold less active than estradiol (E2, EC50 = 0.004 nM). In U2-OS/ERβ cells for all pyrroles no transactivation could be observed, which indicates that they are selective ERα agonists in cellular systems.

(THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS

The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and the linking group –Y-(CH2)n-X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

TRIPHENYL MODIFIED 5-MEMBERED HETEROCYCLES AND THEIR USE AS ANTICANCER AND ANTIINFLAMMATORY AGENTS

The present invention provides 5-membered heterooycles, preferably pyrrole furans and thiophenes, with three phenyl moieties wherein at least one of the three Phenyl moieties is substituted with halogen and alkoxy, halogen and hydrox trihalomethy, and alkoxy, trihatomethyl and hydroxy or halogen and alky, an wherein a second phenyl moiety is substituted with at least hydroxy or alkoxy The compounds of the invention show antiproliferative effects and inhibitory effects on cyclooxygenases (COX-1 and COX-2). Therefore the invention is also directed to the use of said compounds for the manufacture of a pharmaceutic composition for prevention and treatment of cancer and/or inflammatory diseases The invention further concerns a method for treating cancer or an inflammator disease, which comprises the step of administering to a patient suffering from that disease a therapeutically effective amount of at least one of said compounds.

Aminoethylphenoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithiasis

Novel aminoethylphenoxyacetic acid derivatives represented by the general formula: STR1(wherein R 1 represents a hydrogen atom, a lower alkyl group or an aralkyl group; R 2 represents a hydrogen atom or a halogen atom; the carbon atom marked with (R) repr